Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023 08:00 ET
|
Ayala Pharmaceuticals
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT,...
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023 08:00 ET
|
Ayala Pharmaceuticals
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss...
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 17:05 ET
|
Ayala Pharmaceuticals
ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose) Tumor response,...
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023 13:20 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023...
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it will present a...
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
March 03, 2023 08:00 ET
|
Ayala Pharmaceuticals
Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase 2 segment of RINGSIDE are planned for presentation at a medical meeting in 2023 ...
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
February 10, 2023 07:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a...
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
November 17, 2022 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
November 16, 2022 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 04, 2022 08:00 ET
|
Ayala Pharmaceuticals
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing...